FITZGERALD EDWARD M 4

4 · Parabilis Medicines, Inc. · Filed Jun 15, 2026

AI-generated summary of this filing

Updated Jun 15, 2026

Parabilis (PBLS) Director Edward Fitzgerald Converts Preferred to Common Stock

What Happened

Edward M. Fitzgerald, a director of Parabilis Medicines, converted a set of preferred securities into a total of 31,797 shares of common stock. The Form 4 lists six conversion transactions (transaction code C) dated June 11, 2026; no cash price is shown because these were conversions of existing preferred shares rather than open‑market purchases or sales.
The conversions were automatic and occurred in connection with the company's initial public offering: per the filing footnotes, Series B, Series C and Series F preferred shares converted into common stock immediately prior to the closing of the IPO. The filing does not show a cash value paid for the shares (N/A).

Key Details

Transaction dates: conversions reported as June 11, 2026; IPO closing and automatic conversions occurred immediately prior to June 9, 2026 (per footnotes).
Shares acquired via conversion: 31,797 common shares in total (sum of six conversion entries: 5,539; 3,878; 5,271; 5,332; 3,666; 8,111).
Prices/consideration: N/A — these were conversions of preferred into common (not purchases or sales).
Conversion ratios (from filing footnotes): Series B converted at 1 → 1.0389; Series C at 1 → 1.0578; Series F at 1 → 0.6498.
Shares owned after transaction: not specified in the excerpt provided here — see the full Form 4 for post‑transaction beneficial ownership.
Filing: Form 4 filed June 15, 2026 reporting the transactions linked to the IPO period; consult the full filing for any timeliness flags or additional notes.

Context

These were conversions of preferred stock into common stock tied to the IPO, not purchases or sales. Conversions typically do not involve cash changing hands and are a structural change in security type ahead of public trading.
Such conversions increase the insider's common‑share count (and potential liquidity) but are not necessarily a signal of buying or selling intent. For complete context (post‑transaction holdings, any subsequent sales, or restrictions), review the full Form 4 and related disclosures.

Form 4

Period: 2026-06-09

Director

Transactions

Conversion
Common Stock
[F1]
2026-06-11+5,539→ 5,539 total
Conversion
Common Stock
[F2]
2026-06-11+3,878→ 9,417 total
Conversion
Common Stock
[F3]
2026-06-11+5,271→ 14,688 total
Conversion
Series B Preferred Stock
[F1]
2026-06-11+5,332→ 0 total
→ Common Stock (5,539 underlying)
Conversion
Series C Preferred Stock
[F2]
2026-06-11+3,666→ 0 total
→ Common Stock (3,878 underlying)
Conversion
Series F Preferred Stock
[F3]
2026-06-11+8,111→ 0 total
→ Common Stock (5,271 underlying)

Footnotes (3)

[F1]Each share of Series B Preferred Stock was convertible into Common Stock on a 1 to 1.0389 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the "IPO"). The Series B Preferred Stock had no expiration date.
[F2]Each share of Series C Preferred Stock was convertible into Common Stock on a 1 to 1.0578 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the "IPO"). The Series C Preferred Stock had no expiration date.
[F3]Each share of Series F Preferred Stock was convertible into Common Stock on a 1 to 0.6498 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the "IPO"). The Series F Preferred Stock had no expiration date.

Signature

/s/ Teresa Jurgensen, Attorney-in-Fact|2026-06-15

1 file